HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Bruin, M. L. Articles by Hoes, A. W. Search for Related Content PubMed PubMed Citation Articles by De Bruin, M. L. Articles by Hoes, A. W. Social Bookmarking                What's this?

Predicting Cardiac Arrhythmias and Sudden Death in Diabetic Users of Proarrhythmic Drugs

¹ Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands
² Julius Centre for Health Sciences and Primary Care, University Medical Centre, Utrecht, the Netherlands
³ Environmental Epidemiology Unit, Medical Research Council, Southampton University Hospital, Southampton, U.K.

Address correspondence and reprint requests to M.L. De Bruin, PharmD, Utrecht Institute for Pharmaceutical Sciences, Department of Pharmacoepidemiology and Pharmacotherapy, P.O. Box 80082, 3508 TB Utrecht, Netherlands. E-mail: m.l.debruin@pharm.uu.nl

Abbreviations: ROC, receiver operator characteristic • QTc, corrected QT

The first 20% of the full text of this article appears below.

	INTRODUCTION

 
In diabetic patients, the corrected QT (QTc) interval is relatively long (1). In accordance with the concept of "reduced repolarization reserve" (2), a subsequent increase in QTc interval by proarrhythmic drugs may lead to cardiac arrhythmias and sudden death. Recently, it was shown that patients with diabetes are at increased risk of drug-induced arrhythmias (3). We developed a decision tool to predict the risk of serious ventricular arrhythmias and sudden death among diabetic users of nonantiarrhythmic proarrhythmic drugs.

	RESEARCH DESIGN AND METHODS

 
A cohort study among 61,280 diabetic patients using nonantiarrhythmic proarrhythmic medication (amitriptyline, astemizole, chloroquine, chlorpromazine, cisapride, clarithromycin, clomipramine, cotrimoxazole, diphenhydramine/dimenhydrinate, domperidone, doxepine, droperidol, erythromycin, grepafloxacin, halofantrine, haloperidol, indapamide, ketanserin, lidoflazine, mianserine, pentamidine, pimozide, probucol, promethazine, protriptyline, sulfamethoxazole, sultopride, tacrolimus, terfenadine, terodiline, thioridazine, trimethoprim, and zimeldine) (4) in the General Practice Research Database (1987–2001) was performed. This database contains computerized medical records of 650 general practices, including 6.5% of the population of England and Wales. Diabetic patients were followed from the 1st day of prescription of any nonantiarrhythmic proarrhythmic drug. Follow-up was censored when the duration of (one of) the prescription(s) had elapsed, when the study outcome occurred, in case of death, upon exit from the study population, or at the end of the study period, whichever of these events came first. The combined study outcome included ventricular tachycardia, ventricular fibrillation and flutter, cardiac . . . [Full Text of this Article]

	RESULTS

 

	CONCLUSIONS

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E M W van de Garde, E Hak, P C Souverein, A W Hoes, J M M van den Bosch, and H G M Leufkens Statin treatment and reduced risk of pneumonia in patients with diabetes Thorax, November 1, 2006; 61(11): 957 - 961. [Abstract] [Full Text] [PDF]